26/02/2024 – AB Science today announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) regarding its New Drug Submission (NDS) for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) Download PDF Post navigationPreviousPrevious post:AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines AgencyNextNext post:Live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CETRelated PostsSummary of the webcast held on January 28, 202529 January 2025Summary of the webcast held on December 16, 202417 December 2024AB Science webcast of December 16, 202416 December 2024Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET11 December 2024AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease28 October 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS17 October 2024
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease28 October 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS17 October 2024
